BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37296913)

  • 1. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
    Bacchiani M; Salamone V; Massaro E; Sandulli A; Mariottini R; Cadenar A; Di Maida F; Pradere B; Mertens LS; Longoni M; Krajewski W; Del Giudice F; D'Andrea D; Laukhtina E; Shariat SF; Minervini A; Moschini M; Mari A; On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of
    Bertolaso P; Brouste V; Cazeau AL; de Clermont-Gallerande H; Bladou F; Cabart M; Lefort F; Gross-Goupil M
    Clin Genitourin Cancer; 2022 Jun; 20(3):297-297.e6. PubMed ID: 35101381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
    Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
    Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
    Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of [
    Eulitt PJ; Altun E; Sheikh A; Wong TZ; Woods ME; Rose TL; Wallen EM; Pruthi RS; Smith AB; Nielsen ME; Whang YE; Kim WY; Godley PA; Basch EM; David GU; Ramirez J; Deal AM; Rathmell WK; Chen RC; Bjurlin MA; Lin W; Lee JK; Milowsky MI
    Clin Genitourin Cancer; 2020 Oct; 18(5):378-386.e1. PubMed ID: 32147364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.
    Aydh A; Abufaraj M; Mori K; Quhal F; Pradere B; Motlagh RS; Mostafaei H; Karakiewicz PI; Shariat SF
    Arab J Urol; 2020 Dec; 19(1):59-66. PubMed ID: 33763249
    [No Abstract]   [Full Text] [Related]  

  • 10. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of
    Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
    Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT for staging of penile cancer.
    Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]FDG PET/MRI in rectal cancer.
    Crimì F; Valeggia S; Baffoni L; Stramare R; Lacognata C; Spolverato G; Albertoni L; Spimpolo A; Evangelista L; Zucchetta P; Cecchin D; Pucciarelli S
    Ann Nucl Med; 2021 Mar; 35(3):281-290. PubMed ID: 33517562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma.
    Dong Y; Zhang X; Wang S; Chen S; Ma C
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):438-446. PubMed ID: 25996974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [
    Girard A; Dercle L; Vila-Reyes H; Schwartz LH; Girma A; Bertaux M; Radulescu C; Lebret T; Delcroix O; Rouanne M
    Eur Radiol; 2023 Apr; 33(4):2821-2829. PubMed ID: 36422645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.